At Boehringer Ingelheim, we are providing new hope for patients by taking cancer on. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
1. Torre LA, et al. CA Cancer J Clin 2015;65(2):87–108.
2. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr/Pages/burden_sel.aspx (Accessed: 3 July 2017).
3. Schvartsman G, et al. Ther Adv Med Oncol 2016;8(6):460–73.
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.1
1. GIOTRIF® Summary of Product Characteristics 2018
Production date: May 2020